Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Cerilliant
Deloitte
Colorcon
Accenture
AstraZeneca
Chubb
Novartis
Julphar
Merck
Express Scripts

Generated: October 19, 2017

DrugPatentWatch Database Preview

Fluciclovine f-18 - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for fluciclovine f-18 and what is the scope of fluciclovine f-18 freedom to operate?

Fluciclovine f-18
is the generic ingredient in one branded drug marketed by Blue Earth and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Fluciclovine f-18 has thirty-three patent family members in thirteen countries.

One supplier is listed for this compound.

Summary for Generic Name: fluciclovine f-18

US Patents:2
Tradenames:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Bulk Api Vendors: see list2
Clinical Trials: see list5
Patent Applications: see list16
Drug Prices:see low prices
DailyMed Link:fluciclovine f-18 at DailyMed

Pharmacology for Ingredient: fluciclovine f-18

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Blue Earth
AXUMIN
fluciclovine f-18
SOLUTION;INTRAVENOUS208054-001May 27, 2016RXYesYes► Subscribe► Subscribe► Subscribe
Blue Earth
AXUMIN
fluciclovine f-18
SOLUTION;INTRAVENOUS208054-001May 27, 2016RXYesYes► Subscribe► SubscribeY ► Subscribe
Blue Earth
AXUMIN
fluciclovine f-18
SOLUTION;INTRAVENOUS208054-001May 27, 2016RXYesYes► Subscribe► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: fluciclovine f-18

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,758,724Unnatural amino acid radiolabeling precursor► Subscribe
5,817,776 Amino acid analogs for tumor imaging► Subscribe
9,381,259Precursor compound of radioactive halogen-labeled organic compound► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: fluciclovine f-18

Country Document Number Estimated Expiration
European Patent Office1978015► Subscribe
South Korea20130101158► Subscribe
Japan5684333► Subscribe
Canada2237218► Subscribe
Japan2007246535► Subscribe
World Intellectual Property Organization (WIPO)2007063824► Subscribe
South Korea20080071146► Subscribe
Japan5635225► Subscribe
Taiwan200800869► Subscribe
Norway20082877► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Daiichi Sankyo
Novartis
Medtronic
Cipla
Citi
Chinese Patent Office
Federal Trade Commission
QuintilesIMS
Teva
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot